Is Your Paper Ready for Frontiers in Immunology? The Section-Based Submission System

This is where Frontiers in Immunology diverges from nearly every other immunology journal. You don't just submit "to the journal." You submit to a specific specialty section, and that section determines which editors handle your paper, which reviewers evaluate it, and what expertise lens is applied to your work.

The sections include Cancer Immunology and Immunotherapy, Autoimmune and Autoinflammatory Disorders, Clinical Immunology (which is not the same thing as the section called Immunological Tolerance and Regulation), Mucosal Immunity, Viral Immunology, Molecular Innate Immunity, NK and Innate Lymphoid Cell Biology, Vaccines and Molecular Therapeutics, Primary Immunodeficiencies, Inflammation, and more.

Getting the section right matters more than most authors realize. A paper on tumor-infiltrating lymphocytes might fit Cancer Immunology, but if the main finding is about a signaling pathway that happens to be studied in the tumor context, Molecular Innate Immunity or T Cell Biology might be better homes. Section editors know their domain deeply. If your paper lands in front of an editor whose expertise doesn't match your work's core contribution, you'll get reviewers who focus on the wrong things.

The practical test: Look at the section's recent publications. If you can find 5-10 papers from the last two years that your manuscript would cite or that would cite yours, you're in the right section. If you can't find any, you're probably in the wrong one.

A common mistake is defaulting to the broadest-sounding section when your work is specialized. Clinical Immunology sounds like it covers everything clinical, but it has specific editorial preferences. A paper about B cell responses in lupus belongs in Autoimmune and Autoinflammatory Disorders, not Clinical Immunology, even though lupus is obviously a clinical disease. The section name describes the editorial lens, not the disease category.

Most journals send your paper to 2-3 reviewers, collect their reports, and forward them to you with an editorial decision. Frontiers does something different, and it genuinely changes the experience.

The process starts when a handling editor (called the "associate editor" at Frontiers) assigns your paper to a review editor. That review editor then selects 2-3 reviewers. So far, standard. But here's where it diverges: the review editor doesn't just collect reports and pass them along. They actively coordinate between the reviewers and the authors during the revision process. If Reviewer 1 asks for an experiment that Reviewer 2 thinks is unnecessary, the review editor can mediate that disagreement before you're stuck trying to satisfy contradictory demands.

This mediation is genuinely useful. Anyone who's been through traditional peer review has received conflicting reviewer comments with an editor's decision letter that essentially says "address all concerns." At Frontiers, the review editor is supposed to synthesize the feedback into a coherent set of expectations. In practice, some review editors do this better than others, but the structural incentive is toward resolution rather than accumulation of demands.

Another difference: reviewer identities are disclosed upon acceptance. Your reviewers' names appear in the published paper. This creates accountability in both directions. Reviewers tend to be more constructive when their names will be attached to the review. They're less likely to demand a completely new set of experiments or dismiss a paper's premise without explanation. Authors, in turn, know that the people evaluating their work are willing to stand behind their assessment publicly.

The flip side is that some researchers decline to review for Frontiers precisely because of this transparency. If you're reviewing a paper from a senior colleague's lab and you have reservations, putting your name on a critical review has professional consequences. This dynamic can push reviewer pools toward more junior researchers who are less established in the field's power structures, which is sometimes a feature and sometimes a limitation.

Frontiers' editorial philosophy is that journals should evaluate whether research is scientifically sound, not whether editors think it will be highly cited. This is a real philosophical commitment, not marketing language. It means the evaluation criteria are genuinely different from what you'd face at Nature Immunology or Immunity.

What the reviewers are checking:

• Are the methods appropriate for the questions being asked?
• Are the controls adequate?
• Do the statistical analyses support the conclusions drawn?
• Is the data presentation clear and complete?
• Are the conclusions proportional to the evidence?

What the reviewers are not checking (or at least, shouldn't be):

• Is this finding "exciting enough"?
• Will this paper generate a lot of citations?
• Does this advance represent a major conceptual breakthrough?

In practice, this distinction matters most for certain types of papers. Negative results, replication studies, well-executed descriptive work, and methodological papers all have a realistic path at Frontiers in Immunology. These are paper types that routinely get desk-rejected at higher-IF journals not because the science is bad, but because the editorial calculus favors novelty over completeness.

That said, "we evaluate validity, not impact" doesn't mean anything goes. If your experimental design has gaps, if your statistical approach doesn't match your data structure, if your conclusions overreach your evidence, you'll get rejected. The 60% acceptance rate means 40% of papers don't make it, and most of those fail on methodological grounds.

Understanding why papers get rejected here is more useful than understanding why they get accepted. Here are the patterns that trip up immunology researchers.

Overstated conclusions from correlative data. You've found that patients with higher levels of cytokine X have worse outcomes in disease Y. You conclude that cytokine X drives disease progression. The reviewers will flag this immediately. Correlation with outcome data doesn't establish mechanism, and Frontiers reviewers, despite the journal's reputation for accessibility, are rigorous about this distinction. If you don't have functional data (blocking experiments, knockout models, or at least a convincing interventional approach), frame your conclusions as associations, not causal claims.

Flow cytometry panels without proper controls. This one is specific to immunology. If you're characterizing immune cell populations using flow cytometry, the reviewers will check your gating strategy, your FMO controls, and your compensation. Papers that present complex multicolor panels without adequate supplementary figures showing the gating hierarchy get sent back. Include a supplementary figure with your full gating strategy, every time.

Underpowered clinical cohort studies. You've collected samples from 12 patients and 8 controls and you're reporting differences in immune cell frequencies. Unless the effect size is enormous, this won't survive statistical scrutiny. Frontiers reviewers, particularly in Clinical Immunology sections, increasingly expect power calculations or at least honest discussion of sample size limitations. Don't bury a sample size of 15 in the methods and hope nobody notices.

Review articles that don't add perspective. Frontiers publishes a large number of reviews, and the bar for these is often misunderstood. A literature summary isn't enough. The section editors want reviews that synthesize, identify gaps, and offer a framework. If your review reads like a structured bibliography, "Study A found X, Study B found Y, Study C found Z," it won't clear review. Take a position. Argue for a model. Identify what the field is getting wrong.

Before submitting, running your manuscript through a pre-submission review can catch several of these issues, particularly overstatement of conclusions and gaps in statistical reporting, before your paper reaches the editorial stage.

These three journals serve different purposes in an immunology researcher's career, and understanding the positioning helps you submit to the right one.

The comparison isn't really about quality. It's about what each journal is selecting for.

Nature Immunology wants papers that change how immunologists think about a problem. If you've discovered a new cell type, identified a previously unknown signaling axis, or overturned a long-held assumption about immune regulation, that's Nature Immunology territory. The paper needs to redefine how the field thinks about a problem, not just be technically excellent.

Immunity, published by Cell Press, wants deeply mechanistic stories. A typical Immunity paper follows a discovery through multiple layers of evidence: genetic, biochemical, cellular, and often in vivo. The papers tend to be long, data-dense, and exhaustive. If your story requires six main figures and fifteen supplementary figures to tell properly, Immunity is built for that format.

Frontiers in Immunology wants scientifically valid work that contributes to the field's knowledge base. Your paper doesn't need to rewrite the textbook. It needs to be correct, well-executed, and clearly presented. A careful characterization of immune responses in a specific patient population, a replication study that confirms or challenges a previous finding, a new methodology for measuring cytokine responses, these all have a home at Frontiers.

The honest strategic calculation looks like this: if you have a once-in-a-career finding with broad implications, try Nature Immunology or Immunity first. If you have solid, well-executed work that advances understanding in your subfield without necessarily rewriting the textbook, Frontiers in Immunology is a strong and legitimate choice. Publishing there isn't "settling." It's choosing a journal whose evaluation criteria match what your paper actually offers.

Not every paper needs to aim for the highest possible IF. Here are situations where Frontiers in Immunology is genuinely the best strategic fit.

Your paper is methodologically sound but not "high-impact." You've characterized the immune landscape in a specific disease cohort, or you've validated a finding from another group in a different patient population. This work matters. It advances the field. It just doesn't have the novelty signal that gets past Nature Immunology's desk. Frontiers will evaluate it on its merits.

You need speed and predictability. With ~77 days to decision and a collaborative review model that reduces the back-and-forth of traditional review, Frontiers offers a more predictable timeline than most alternatives. If you're a postdoc on the job market and you need a published paper, not a paper under review at a journal that might desk-reject it in three months, the timeline matters.

Your work is in a niche subfield. Frontiers' section system means your paper is handled by editors and reviewers who actually work in your area. If you study NK cell biology in the context of a rare primary immunodeficiency, you'll get reviewers from the NK and Innate Lymphoid Cell Biology section or Primary Immunodeficiencies who understand the context. At a generalist journal, you might get reviewers who don't appreciate why your finding matters within that specific community.

You want open access without a prohibitive fee. Frontiers is fully open access, and while the APCs aren't cheap, they're lower than Nature Communications (~$6,490) and comparable to many society journals. For researchers with funder mandates for open access, this removes a barrier.

You're publishing a review or methods paper. Frontiers actively publishes these article types and treats them as first-class contributions. Many high-IF immunology journals publish reviews only by invitation. At Frontiers, you can submit an unsolicited review to the appropriate section and have it evaluated on quality.